Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2022-09-12 |
2022-06 |
-0.02 |
N/A |
N/A |
N/A |
2022-05-09 |
2022-03 |
0 |
N/A |
N/A |
N/A |
2022-02-07 |
2021-12 |
0 |
N/A |
N/A |
N/A |
2021-05-06 |
2021-03 |
0 |
N/A |
N/A |
N/A |
2020-07-06 |
2020-03 |
-0.29 |
N/A |
N/A |
N/A |
2020-04-01 |
2019-12 |
0 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2022-07-20 |
Alliance Global Partners |
Upgrade |
|
Buy |
2021-05-04 |
Alliance Global Partners |
Upgrade |
|
Buy |
2020-12-10 |
Jefferies |
Downgrade |
Buy |
Hold |
2020-12-10 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2020-11-25 |
Jefferies |
Upgrade |
|
Buy |
2020-11-25 |
Jefferies |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2022-02-09 |
ABERMAN ZALMAN |
Director |
0.00 |
Purchase |
2019-04-07 |
BEN-YORAM ISRAEL |
Director |
798.49K |
Purchase |
2021-07-14 |
BIRGER PINHAS DORON |
Director |
20.00K |
Stock Award(Grant) |
2020-09-09 |
BRAUN ISAAC |
Director |
83.62K |
Stock Award(Grant) |
2021-05-27 |
CLOVER WOLF CAPITAL, LP |
Beneficial Owner of more than 10% of a Class of Security |
3.12M |
Sale |
2020-09-09 |
GERMAIN MARK S |
Director |
82.57K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2022-03-30 |
Nia Impact Advisors, LLC |
837.90K |
837.90K |
2.59% |
2022-06-29 |
Green Alpha Advisors, LLC |
812.54K |
812.54K |
2.51% |
2022-03-30 |
Meitav Dash Investments Ltd |
167.59K |
167.59K |
0.52% |
2022-03-30 |
Susquehanna International Group, LLP |
156.32K |
156.32K |
0.48% |
2022-03-30 |
Jane Street Group, LLC |
137.47K |
137.47K |
0.42% |
2022-03-30 |
Shelton Capital Management LLC |
128.53K |
128.53K |
0.40% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-05-30 |
Shelton Funds-Green Alpha Fund |
128.53K |
128.53K |
0.40% |
2022-03-30 |
Bridgeway Funds Inc-Ultra Small Company Market Fund |
70.00K |
70.00K |
0.22% |
2022-06-29 |
SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF |
50.51K |
50.51K |
0.16% |
2022-04-29 |
DFA International Core Equity Portfolio |
33.47K |
33.47K |
0.10% |
2022-05-30 |
SPDR Portfolio Developed World ex-US ETF |
33.60K |
33.60K |
0.10% |
2022-05-30 |
Fidelity NASDAQ Composite Index Fund |
25.17K |
25.17K |
0.08% |
Split |
Date |
1 : 10 |
2019-07-25 |
0.005 : 1 |
2007-11-26 |